Germany's Merck open to more M&A for its Life Science division
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 17 2024
0mins
Should l Buy ?
Source: Reuters
Acquisition Plans: Merck is open to further acquisitions in its Life Science business following the announcement of its $600 million purchase of Mirus Bio, with a focus on finding the right targets at the right time and price.
Business Outlook Adjustments: The company has adjusted its growth expectations for its Life Science and Healthcare divisions while raising its mid-term outlook for the electronics sector due to increased demand for AI-related chips.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
